# Iota Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/iota-biosciences

- Industry: Medical Devices & Equipment
- Headquarters: Berkeley, US
- Website: www.iota.bio
- Total disclosed funding: $15M
- Latest round: Series A (May 4, 2018)
- Investors on record: 7

## About

Iota Biosciences, Inc. is a biotechnology company focused on developing advanced bioelectronic devices that bridge biological systems with electronic technology, enhancing treatment options for various medical conditions.Founded in 2017 in Berkeley, US, Iota Biosciences, Inc. specializes in bioelectronics. The company was co-founded by Jose Carmena and Michel Maharbiz, both of whom have extensive backgrounds in bioengineering. As of October 15, 2020, the company was acquired by Astellas Pharma Inc. for USD 127.5 mn, reflecting a significant investment in its innovative technology.Iota Biosciences specializes in advanced bioelectronics, offering innovative solutions that bridge the gap between biological systems and electronic devices. The company develops biocompatible interfaces and implantable devices designed to monitor and modulate biological processes in real-time, serving healthcare providers, research institutions, and technology partners primarily in North America and Europe.Iota Biosciences generates revenue through structured transactions, including direct sales of its bioelectronic devices and partnerships with healthcare organizations. Revenue streams encompass B2B sales agreements and licensing agreements for third-party access to proprietary technology, ensuring steady demand for its offerings.Following the acquisition by Astellas Pharma Inc., Iota Biosciences aims to leverage its resources to expand product lines and enhance its technology offerings. The company is focused on designing new products aimed at chronic pain management and neuromodulation, with plans to enter additional markets in Europe and Asia by 2022. The recent funding of USD 127.5 mn will support these initiatives, facilitating product development and market expansion.

## Funding rounds

- Series A, May 4, 2018, $15M — Shanda Capital, Horizons Ventures, Astellas Pharma Inc., Ironfire Ventures, BOLD Capital Partners, The House Fund, Berkeley SkyDeck Fund

## Investors

- Shanda Capital — Series A
- Horizons Ventures — Series A
- Astellas Pharma Inc. — Series A
- Ironfire Ventures (https://capitalatlas.ai/funds/ironfire-ventures) — Series A
- BOLD Capital Partners (https://capitalatlas.ai/funds/bold-capital-partners) — Series A
- The House Fund (https://capitalatlas.ai/funds/the-house-fund) — Series A
- Berkeley SkyDeck Fund (https://capitalatlas.ai/funds/berkeley-skydeck-fund) — Series A